On November 16th, Pfizer and Astellar jointly announced that their prostate cancer drug XTANDI has been approved by the US Food and Drug Administration (FDA) for the treatment of non metastatic castration sensitive prostate cancer (nmCSPC) patients. XTANDI is currently undergoing review by other regulatory agencies, including the European Medicines Agency. Xtandi is an androgen receptor signaling inhibitor that has received regulatory approval in multiple countries and regions around the world.